Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALE)
NCT04770545Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Sep 2025
- Modality
- PEGylated Peptides
- Countries
- 15
01
Overview
A Phase 3 trial of pegcetacoplan in geographic atrophy (GA), sponsored by Apellis Pharmaceuticals. Started Mar 2021; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04770545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770545.